TxCell SA, a biotechnology company developing personalized cellular immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, has launched its new process industrialization laboratories and technology transfer academy facilities in Sophia Antipolis, France. These new facilities will be primarily dedicated to the improvement of the existing TxCell manufacturing process for its ASTrIA platform as well as to the development of a manufacturing process ...